With advances in next-generation sequencing, whole-exome and genome sequencing (WGES) is now accessible as a tool in many applications. In the clinical setting, WGES is proving to be very valuable for the diagnosis of rare genetic disorders and a key to a more comprehensive disease treatment. These assays rely heavily on bioinformatics processes, and have unique requirements for implementation and validation., though there are currently limited guidelines for how to handle bioinformatics validation in the clinical lab setting for such complex tests. In this talk, we outline our laboratorys approach to tackling the issues faced in implementing clinical WGES, including methods and techniques to validate the assay and interpret the results. Well also detail our experiences offering WGES in clinical care, including our support of the MedSeq and BabySeq projects that are studying the return of genome and exome sequencing results in adults and newborns, respectively, in both healthy individuals and individuals with disease.